Hopewell Sally, Altman Douglas G, Moher David, Schulz Kenneth F
Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
Trials. 2008 Apr 18;9:20. doi: 10.1186/1745-6215-9-20.
The CONSORT Statement provides recommendations for reporting randomized controlled trials. We assessed the extent to which leading medical journals that publish reports of randomized trials incorporate the CONSORT recommendations into their journal and editorial processes.
This article reports on two observational studies. Study 1: We examined the online version of 'Instructions to Authors' for 165 high impact factor medical journals and extracted all text mentioning the CONSORT Statement or CONSORT extension papers. Any mention of the International Committee of Medical Journal Editors (ICMJE) or clinical trial registration were also sought and extracted. Study 2: We surveyed the editor-in-chief, or editorial office, for each of the 165 journals about their journal's endorsement of CONSORT recommendations and its incorporation into their editorial and peer-review processes.
Study 1: Thirty-eight percent (62/165) of journals mentioned the CONSORT Statement in their online 'Instructions to Authors'; of these 37% (23/62) stated this was a requirement, 63% (39/62) were less clear in their recommendations. Very few journals mentioned the CONSORT extension papers. Journals that referred to CONSORT were more likely to refer to ICMJE guidelines (RR 2.16; 95% CI 1.51 to 3.08) and clinical trial registration (RR 3.67; 95% CI 2.36 to 5.71) than those journals which did not.Study 2: Thirty-nine percent (64/165) of journals responded to the on-line survey, the majority were journal editors. Eighty-eight percent (50/57) of journals recommended authors comply with the CONSORT Statement; 62% (35/56) said they would require this. Forty-one percent (22/53) reported incorporating CONSORT into their peer-review process and 47% (25/53) into their editorial process. Eighty-one percent (47/58) reported including CONSORT in their 'Instructions to Authors' although there was some inconsistency when cross checking information on the journal's website. Sixty-nine percent (31/45) of journals recommended authors comply with the CONSORT extension for cluster trials, 60% (27/45) for harms and 42% (19/45) for non-inferiority and equivalence trials. Few journals mentioned these extensions in their 'Instructions to Authors'.
Journals should be more explicit in their recommendations and expectations of authors regarding the CONSORT Statement and related CONSORT extensions papers.
CONSORT声明为报告随机对照试验提供了建议。我们评估了发表随机试验报告的主要医学期刊在其期刊和编辑流程中纳入CONSORT建议的程度。
本文报告了两项观察性研究。研究1:我们检查了165种高影响因子医学期刊的在线“作者须知”,提取了所有提及CONSORT声明或CONSORT扩展文件的文本。还查找并提取了任何提及国际医学期刊编辑委员会(ICMJE)或临床试验注册的内容。研究2:我们就165种期刊中的每一种向其主编或编辑部调查了期刊对CONSORT建议的认可情况及其在编辑和同行评审流程中的纳入情况。
研究1:38%(62/165)的期刊在其在线“作者须知”中提及了CONSORT声明;其中37%(23/62)表示这是一项要求,63%(39/62)在其建议中不太明确。很少有期刊提及CONSORT扩展文件。提及CONSORT的期刊比未提及的期刊更有可能提及ICMJE指南(相对风险2.16;95%置信区间1.51至3.08)和临床试验注册(相对风险3.67;95%置信区间2.36至5.71)。研究2:39%(64/165)的期刊回复了在线调查,大多数是期刊编辑。88%(50/57)的期刊建议作者遵守CONSORT声明;62%(35/56)表示他们会要求这样做。41%(22/53)报告将CONSORT纳入其同行评审流程,47%(25/53)纳入其编辑流程。81%(47/58)报告在其“作者须知”中包含CONSORT,尽管在核对期刊网站上的信息时存在一些不一致。69%(31/45)的期刊建议作者遵守群组试验的CONSORT扩展,60%(27/45)针对危害,42%(19/45)针对非劣效性和等效性试验。很少有期刊在其“作者须知”中提及这些扩展。
期刊应在对作者关于CONSORT声明及相关CONSORT扩展文件的建议和期望方面更加明确。